# EDGAR Filing Document

**Accession Number:** 0001872812
**File Stem:** 0001493152-25-017198
**Filing Date:** 2025-10
**Character Count:** 3168
**Document Hash:** cdcb56590cfe9597505b35af06886726
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-017198.hdr.sgml**: 20251007

**ACCESSION NUMBER**: 0001493152-25-017198

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251007

**FILED AS OF DATE**: 20251007

**DATE AS OF CHANGE**: 20251007

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TC BioPharm (Holdings) plc
- **CENTRAL INDEX KEY:** 0001872812
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41231
- **FILM NUMBER:** 251378231

**BUSINESS ADDRESS:**
- **STREET 1:** MAXIM 1
- **STREET 2:** 2 PARKLANDS WAY
- **CITY:** HOLYTOWN
- **STATE:** X0
- **ZIP:** ML1 4WR
- **BUSINESS PHONE:** 01414337557

**MAIL ADDRESS:**
- **STREET 1:** MAXIM 1
- **STREET 2:** 2 PARKLANDS WAY
- **CITY:** HOLYTOWN
- **STATE:** X0
- **ZIP:** ML1 4WR

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TC BioPharm (Holdings) Ltd
- **DATE OF NAME CHANGE:** 20210721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TC BioPharm Ltd
- **DATE OF NAME CHANGE:** 20210714

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of**

**the Securities Exchange Act of 1934**

**For the month of October 2025**

**Commission File Number 001-41231**

**TC BIOPHARM (HOLDINGS) PLC**

(Translation of registrant's name into English)

**Maxim 1, 2 Parklands Way**

**Holytown, Motherwell, ML1 4WR**

**Scotland, United Kingdom**

**+44 (0) 141 433 7557**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ ☐

<u>TC BioPharm Limited</u>

On October 2, 2025, the directors of TC BioPharm Limited, a subsidiary of TC BioPharm (Holdings) plc, appointed Michael Magnay and Rob Croxen of Alvarez and Marsal Europe LLP ("A&M") as joint administrators to TC BioPharm Limited. A&M are now exploring options for the sale of the business and assets of TC BioPharm Limited, including the intellectual property and R&D assets for the benefit of creditors.

TC BioPharm (Holdings) plc continues to operate as usual outside of the administration process.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **TC BIOPHARM (HOLDINGS) PLC** | **TC BIOPHARM (HOLDINGS) PLC** |
| Date: October 7, 2025 | By: | */s/ Martin Thorp* |
|  |  | Martin Thorp |
|  |  | Chief Financial Officer |

---